6-肼基-1,3,4-三甲基-1H-吡唑并[3,4-b]吡啶 | 175202-00-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 中文名称: 6-肼基-1,3,4-三甲基-1H-吡唑并[3,4-b]吡啶
• 中文别名: 6-肼-1,3,4-三甲基-1H-吡唑啉酮[3,4-B]吡啶
• 英文名称: 6-hydrazinyl-1,3,4-trimethyl-1H-pyrazolo[3,4-b]pyridine
• 英文别名: 1,3,4-trimethyl-1H-pyrazolo[3,4-b]pyrid-6-yl hydrazine；6-hydrazino-1,3,4-trimethyl-1H-pyrazolo[3,4-b]pyridine；(1,3,4-trimethylpyrazolo[3,4-b]pyridin-6-yl)hydrazine
• CAS: 175202-00-3
• 化学式: C₉H₁₃N₅
• mdl: MFCD00067969
• 分子量: 191.236
• InChiKey: NDFXPLOECYNSHX-UHFFFAOYSA-N

物化性质

• 熔点：
  199 °C
• 沸点：
  350.1±52.0 °C(Predicted)
• 密度：
  1.37±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  68.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 安全说明：
  S26
• 危险类别码：
  R36/37/38
• 海关编码：
  2933990090

SDS

Name:	6-Hydrazino-1 3 4-trimethyl-1H-pyrazolo[3 4-b]pyridine 97% Material Safety Data Sheet
Synonym:
CAS:	175202-00-3

Section 1 - Chemical Product MSDS Name:6-Hydrazino-1 3 4-trimethyl-1H-pyrazolo[3 4-b]pyridine 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
175202-00-3	6-Hydrazino-1,3,4-trimethyl-1H-pyrazol	97%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. May cause respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 175202-00-3: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: pale yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 190 - 195 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H13N5
Molecular Weight: 191

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, acids, acid chlorides.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 175202-00-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
6-Hydrazino-1,3,4-trimethyl-1H-pyrazolo[3,4-b]pyridine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
Safety Phrases:
S 36/37 Wear suitable protective clothing and
gloves.
WGK (Water Danger/Protection)
CAS# 175202-00-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 175202-00-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 175202-00-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-肼基-1,3,4-三甲基-1H-吡唑并[3,4-b]吡啶 、 N-[7-(7-Chloro-quinolin-4-ylamino)-heptyl]-2-oxo-acetamide 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 (2E)-N-[7-[(7-chloroquinolin-4-yl)amino]heptyl]-2-[(1,3,4-trimethylpyrazolo[3,4-b]pyridin-6-yl)hydrazinylidene]acetamide
  参考文献：
  名称：

  Design, synthesis and antimalarial activity of a glyoxylylhydrazone library

  摘要：

  Synthesis of a new family of quinolylhydrazone derivatives and evaluation of their activity against a chloroquine-resistant strain of Plasmodium falciparum are described. The best compound displayed an activity 6-fold higher than chloroquine. None of the active compounds were found to inhibit beta-hematin formation in vitro in the same range as chloroquine and five among them displayed lower calculated vacuolar accumulation ratios, suggesting the implication of a different mechanism of action. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.06.056
• 作为产物：
  描述：

  5-氨基-1,3-二甲基吡唑 在 hydrazine hydrate 、 溶剂黄146 、 三溴氧磷 作用下， 以 乙醇 为溶剂， 生成 6-肼基-1,3,4-三甲基-1H-吡唑并[3,4-b]吡啶
  参考文献：
  名称：

  Novel 5-fluorouracil sensitizers for colorectal cancer therapy: Design and synthesis of S1P receptor 2 (S1PR2) antagonists

  摘要：

  DOI：

  10.1016/j.ejmech.2021.113923

文献信息

• [EN] NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE<br/>[FR] AGENTS ANTI-GNRH NON PEPTIDIQUES, COMPOSITIONS PHARMACEUTIQUES ET PROCEDES D'UTILISATION
  申请人：PFIZER

  公开号：WO2003106446A1

  公开（公告）日：2003-12-24

  Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression o£ gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.

  描述了能够抑制促性腺激素释放激素作用的非肽类GnRH药物。这些化合物及其药用可接受的盐类、前药和活性代谢物适用于治疗哺乳动物的生殖障碍和类固醇激素依赖性肿瘤，以及调节生育能力，其中表明需要抑制促性腺激素释放。还描述了合成这些化合物和在其制备中有用的中间体的方法。
• Selective Inhibitors of the Protein Tyrosine Phosphatase SHP2 Block Cellular Motility and Growth of Cancer Cells in vitro and in vivo
  作者：Stefanie Grosskopf、Chris Eckert、Christoph Arkona、Silke Radetzki、Kerstin Böhm、Udo Heinemann、Gerhard Wolber、Jens-Peter von Kries、Walter Birchmeier、Jörg Rademann

  DOI：10.1002/cmdc.201500015

  日期：2015.5

  adenocarcinoma (HPAF) cells, as indicated by a decrease in the minimum neighbor distances of cells. Moreover, 25 inhibited cell colony formation in the non‐small‐cell lung cancer cell line LXFA 526L in soft agar. Finally, 25 was observed to inhibit tumor growth in a murine xenograft model. Therefore, the novel specific compound 25 strengthens the hypothesis that SHP2 is a relevant protein target for the inhibition

  酪氨酸蛋白磷酸酶SHP2（src同源区域2域磷酸酶； PTPN11）的选择性抑制剂是通过化学合成和基于结构的合理设计相结合而产生的，该酶在许多人类肿瘤中均被解除调节。制备了70种吡啶并唑-4-亚甲基肼基苯磺酸盐，并在酶分析中进行了评估。使用新生成的SHP2晶体结构在计算机上模拟了活性抑制剂的结合模式。最强大的化合物GS‐493（4 ‐ （2 Z）‐2‐ [1、3‐双（4‐硝基苯基）‐5‐oxo‐1,5‐二氢‐4 H‐吡唑‐4‐liden]]肼基苯磺酸；25）抑制SHP2，IC 50值为71±15 n M在酶检测中，对SHP2的活性比对相关SHP1和PTP1B的活性高29到45倍。在细胞培养实验中，发现化合物25可以阻断肝细胞生长因子（HGF）刺激的人胰腺癌（HPAF）细胞的上皮-间质转化，这通过最小最小细胞距离的减少来表明。此外，在软琼脂中，有25种抑制了非小细胞肺癌LXFA 526L细
• Non-peptide GnRH agents, pharmaceutical compositions and methods for their use
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：US20040014787A1

  公开（公告）日：2004-01-22

  Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.

  本文描述了能够抑制促性腺激素释放激素作用的非肽类GnRH（促性腺激素释放激素）药物。这些化合物及其药学上可接受的盐、前药和活性代谢物适用于治疗哺乳动物生殖障碍和类固醇激素依赖性肿瘤，以及调节生育，其中需要抑制促性腺激素释放。本文还描述了合成这些化合物和其制备中有用的中间体的方法。
• Estrogen receptor modulators
  申请人：CHIRON CORPORATION

  公开号：US20040077701A1

  公开（公告）日：2004-04-22

  Estrogen receptor-modulating pyrazole compounds are described in addition to methods and compositions for treating or preventing estrogen receptor-mediated disorders. The compounds described have been found to have unexpected and surprising activity in modulating estrogen receptor activity. Thus, the compounds of the present invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer's disease.

  本文描述了调节雌激素受体的吡唑化合物，以及用于治疗或预防雌激素受体介导的疾病的方法和组合物。所述化合物已被发现具有意外和惊人的调节雌激素受体活性的活性。因此，本发明的化合物在预防或治疗雌激素受体介导的疾病，如骨质疏松症、乳腺和子宫内膜癌、动脉硬化和阿尔茨海默病中具有实用性。
• Novel phthalazinones
  申请人：——

  公开号：US20040127707A1

  公开（公告）日：2004-07-01

  The compounds of formula I in which R1, R2, R3, R4 and R5 have the meanings as given in the description are PDE4/7 inhibitors.

  式I中，当R1、R2、R3、R4和R5的含义如描述所述时，这些化合物是PDE4/7抑制剂。